JP2018511634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511634A5 JP2018511634A5 JP2017553956A JP2017553956A JP2018511634A5 JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5 JP 2017553956 A JP2017553956 A JP 2017553956A JP 2017553956 A JP2017553956 A JP 2017553956A JP 2018511634 A5 JP2018511634 A5 JP 2018511634A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- cancer
- dihydro
- solvent
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021009106A JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015076639 | 2015-04-15 | ||
| CNPCT/CN2015/076639 | 2015-04-15 | ||
| PCT/CN2016/079251 WO2016165626A1 (en) | 2015-04-15 | 2016-04-14 | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009106A Division JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511634A JP2018511634A (ja) | 2018-04-26 |
| JP2018511634A5 true JP2018511634A5 (enExample) | 2019-05-23 |
| JP7320741B2 JP7320741B2 (ja) | 2023-08-04 |
Family
ID=57125563
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553956A Active JP7320741B2 (ja) | 2015-04-15 | 2016-04-14 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2021009106A Active JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A Withdrawn JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009106A Active JP7383652B2 (ja) | 2015-04-15 | 2021-01-22 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| JP2023190552A Withdrawn JP2024012540A (ja) | 2015-04-15 | 2023-11-08 | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10351559B2 (enExample) |
| EP (2) | EP4119559A1 (enExample) |
| JP (3) | JP7320741B2 (enExample) |
| KR (2) | KR20240049684A (enExample) |
| CN (2) | CN107531682B (enExample) |
| AU (1) | AU2016248376B2 (enExample) |
| CA (1) | CA2981746C (enExample) |
| EA (1) | EA035680B1 (enExample) |
| IL (2) | IL287740B2 (enExample) |
| MX (1) | MX381053B (enExample) |
| NZ (1) | NZ735715A (enExample) |
| SG (1) | SG11201707984TA (enExample) |
| TW (4) | TWI876835B (enExample) |
| WO (1) | WO2016165626A1 (enExample) |
| ZA (1) | ZA201706392B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| DK2797888T3 (en) | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| AU2016248376B2 (en) * | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
| CN112714762A (zh) * | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| GEP20237494B (en) * | 2018-10-31 | 2023-04-10 | Servier Lab | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same |
| CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
| CN111484489B (zh) * | 2019-01-25 | 2023-05-23 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
| EP3937936A4 (en) * | 2019-03-15 | 2022-12-28 | Forma Therapeutics, Inc. | INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| PL4125842T3 (pl) * | 2020-04-03 | 2024-10-14 | Beigene, Ltd. | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| JP2025519981A (ja) * | 2022-06-08 | 2025-06-30 | マップキュア，エルエルシー | Ｂ－ｒａｆ阻害剤によるがんの治療方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767687B2 (en) | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| WO2007067444A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| AU2007254325B2 (en) | 2006-05-15 | 2012-05-10 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| CA2661334C (en) | 2006-08-23 | 2011-11-29 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| JP2010502706A (ja) | 2006-09-07 | 2010-01-28 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害活性を有するフェネチルアミド誘導体 |
| CA2686379A1 (en) | 2007-05-04 | 2008-11-13 | Irm Llc | Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors |
| US20100197924A1 (en) * | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| JP5808818B2 (ja) * | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| DK2797888T3 (en) * | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
| AU2016248376B2 (en) | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
-
2016
- 2016-04-14 AU AU2016248376A patent/AU2016248376B2/en active Active
- 2016-04-14 SG SG11201707984TA patent/SG11201707984TA/en unknown
- 2016-04-14 TW TW113101605A patent/TWI876835B/zh active
- 2016-04-14 CA CA2981746A patent/CA2981746C/en active Active
- 2016-04-14 TW TW112101259A patent/TWI832668B/zh active
- 2016-04-14 JP JP2017553956A patent/JP7320741B2/ja active Active
- 2016-04-14 IL IL287740A patent/IL287740B2/en unknown
- 2016-04-14 TW TW105111715A patent/TWI736531B/zh active
- 2016-04-14 KR KR1020247006890A patent/KR20240049684A/ko not_active Ceased
- 2016-04-14 EP EP22179294.8A patent/EP4119559A1/en active Pending
- 2016-04-14 EP EP16779601.0A patent/EP3283486B1/en active Active
- 2016-04-14 MX MX2017013219A patent/MX381053B/es unknown
- 2016-04-14 TW TW110125410A patent/TWI792406B/zh active
- 2016-04-14 US US15/565,807 patent/US10351559B2/en active Active
- 2016-04-14 EA EA201792254A patent/EA035680B1/ru unknown
- 2016-04-14 KR KR1020177033101A patent/KR102643609B1/ko active Active
- 2016-04-14 CN CN201680021109.0A patent/CN107531682B/zh active Active
- 2016-04-14 WO PCT/CN2016/079251 patent/WO2016165626A1/en not_active Ceased
- 2016-04-14 NZ NZ735715A patent/NZ735715A/en unknown
- 2016-04-14 CN CN202110419671.1A patent/CN113307805A/zh active Pending
-
2017
- 2017-09-21 ZA ZA2017/06392A patent/ZA201706392B/en unknown
- 2017-11-09 IL IL255555A patent/IL255555B/en unknown
-
2021
- 2021-01-22 JP JP2021009106A patent/JP7383652B2/ja active Active
-
2023
- 2023-11-08 JP JP2023190552A patent/JP2024012540A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528199A5 (enExample) | ||
| JP2020033359A5 (enExample) | ||
| AU2016260279B2 (en) | Crystals of azabicyclic compound | |
| JP6998969B2 (ja) | （ｓ）－２－（（２－（（ｓ）－４－（ジフルオロメチル）－２－オキソオキサゾリジン－３－イル）－５，６－ジヒドロベンゾ［ｆ］イミダゾ［１，２－ｄ］［１，４］オキサゼピン－９－イル）アミノ）プロパンアミドの多形体及び固体形態と、生産方法 | |
| CN107531682A (zh) | B‑raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 | |
| JP2019515024A (ja) | ボルチオキセチンのパモ酸塩及びその結晶形 | |
| JP2020517611A5 (enExample) | ||
| KR102666017B1 (ko) | 엔잘루타미드 결정형의 제조 방법 | |
| CA3142088A1 (en) | Compound used as kinase inhibitor and application thereof | |
| CA3009713A1 (en) | Crystalline forms of ponesimod and preparation method thereof | |
| JP2023509944A5 (enExample) | ||
| CA3083022A1 (en) | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production | |
| JP6816036B2 (ja) | ヒストン脱アセチル化阻害剤の結晶形態 | |
| JP2020143160A (ja) | アクリジニウム臭化物の製造方法 | |
| JP2013541589A5 (enExample) | ||
| JP6676626B2 (ja) | アシルチオウレア化合物のメシル酸塩の結晶及びその製造方法 | |
| ES2727667T3 (es) | Polimorfos de lenalidomida | |
| JP2020530497A (ja) | ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態 | |
| CN111315748B (zh) | 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮晶体 | |
| JP2013184902A5 (ja) | リファキシミン結晶 | |
| JP2010229098A (ja) | イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形 | |
| JP2015521635A5 (enExample) | ||
| JP6165335B2 (ja) | ゲフィチニブの新規な結晶形およびその製造方法 | |
| WO2018214877A1 (zh) | 一种地佐辛晶型及其制备方法 | |
| JPWO2011152411A1 (ja) | チエノピリミジン誘導体の結晶 |